| Literature DB >> 21686153 |
Milan Mladenović1, Mirjana Mihailović, Desanka Bogojević, Sanja Matić, Neda Nićiforović, Vladimir Mihailović, Nenad Vuković, Slobodan Sukdolak, Slavica Solujić.
Abstract
The series of fifteen synthesized 4-hydroxycoumarin derivatives was subjected to antioxidant activity evaluation in vitro, through total antioxidant capacity, 1,1-diphenyl-2-picryl-hydrazyl (DPPH), hydroxyl radical, lipid peroxide scavenging and chelating activity. The highest activity was detected during the radicals scavenging, with 2b, 6b, 2c, and 4c noticed as the most active. The antioxidant activity was further quantified by the quantitative structure-activity relationships (QSAR) studies. For this purpose, the structures were optimized using Paramethric Method 6 (PM6) semi-empirical and Density Functional Theory (DFT) B3LYP methods. Bond dissociation enthalpies of coumarin 4-OH, Natural Bond Orbital (NBO) gained hybridization of the oxygen, acidity of the hydrogen atom and various molecular descriptors obtained, were correlated with biological activity, after which we designed 20 new antioxidant structures, using the most favorable structural motifs, with much improved predicted activity in vitro.Entities:
Keywords: 4-hydroxycoumarins; BDEs; DFT; QSAR; antioxidant activity in vitro; design
Mesh:
Substances:
Year: 2011 PMID: 21686153 PMCID: PMC3116159 DOI: 10.3390/ijms12052822
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Total antioxidant capacity and DPPH radical scavenging activity of synthesized coumarin derivatives in vitro.
| 121.46 ± 0.28 | 97.45 ± 0.31 | 133.70 ± 0.24 | 87.47 ± 0.24 | |
| 278.24 ± 0.36 | 47.65 ± 0.24 | 6.2 ± 0.11 | 4.6 ± 0.26 | |
| 54.08 ± 0.76 | 197.62 ± 0.21 | 44.93 ± 0.16 | 8.80 ± 0.14 | |
| 138.32 ± 0.87 | 84.57 ± 0.65 | 41.64 ± 0.14 | 9.93 ± 0.22 | |
| 212.12 ± 0.26 | 50.59 ± 0.12 | 5.14 ± 0.06 | 2.45 ± 0.17 | |
| 324.01 ± 0.28 | 35.69 ± 0.17 | 246.63 ± 0.31 | 135.01 ± 0.31 | |
| 106.64 ± 0.15 | 99.71 ± 0.28 | 37.76 ± 0.21 | 11.28 ± 0.19 | |
| 514.24 ± 0.64 | 33.35 ± 0.24 | 4.94 ± 0.08 | 6.97 ± 0.25 | |
| 86.14 ± 0.95 | 132.66 ± 0.16 | 29.07 ± 0.04 | 9.22 ± 0.17 | |
| 742.67 ± 0.28 | 17.25 ± 0.15 | 4.72 ± 0.03 | 3.54 ± 0.32 | |
| 198.84 ±0.24 | 53.16 ± 0.09 | 68.56 ± 0.07 | 66.54 ± 0.26 | |
| 164.61 ± 0.32 | 72.35 ± 0.15 | 115.42 ± 0.15 | 94.30 ± 0.24 | |
| 224.26 ± 0.31 | 46.67 ± 0.11 | 161.73 ± 0.46 | 93.58 ± 0.17 | |
| 219.94 ± 0.56 | 47.18 ± 0.28 | 140.48 ± 0.26 | 60.31 ± 0.06 | |
| 82.22 ± 0.96 | 136.94 ± 0.53 | 13.72 ± 0.25 | 4.79 ± 0.03 | |
| 26.76 ± 0.48 | 219.43 ± 0.89 | 78.25 ± 0.11 | 76.41 ± 0.05 | |
| / | / | 24.17 ± 0.07 | 15.61 ± 0.04 | |
| / | / | 8.62 ± 0.02 | 6.05 ± 0.01 | |
Total antioxidant capacity of the coumarin derivatives expressed as μg equivalents of ascorbic acid per milliliter;
Total antioxidant capacity of the coumarin derivatives; TAC50, the concentration of coumarin required to inhibit 50% of Mo(VI) reduction;
DPPH radical scavenging activity;
Results are mean values ± SD from at least three experiments.
Figure 1.(a) DPPH radical scavenging activity in the 60th minute; and (b) determination of hydroxyl radical scavenging activity, in vitro.
Lipid peroxide, hydroxyl radical scavenging and chelating effect of coumarin derivatives in vitro.
| 26.31 ± 0.31 | 55.23 ± 0.22 | 55.23 ± 0.32 | 17.77 ± 0.15 | 475.24 ± 0.21 | |
| 7.77 ± 0.12 | 16.85 ± 0.15 | 13.01 ± 0.14 | 17.19 ± 0.06 | 45.0 ± 0.54 | |
| 12.08 ± 0.12 | 28.07 ± 0.41 | 10.46 ± 0.28 | 32.21 ± 0.41 | 57.35 ± 0.34 | |
| 18.96 ± 0.04 | 37.89 ± 0.28 | 80.95 ± 0.24 | 84.04 ± 0.02 | 62.5 ± 0.11 | |
| <3.901 | 10.13 ± 0.16 | 10.76 ± 0.16 | 14.32 ± 0.15 | 28.64 ± 0.28 | |
| 76.17 ± 0.25 | 216.85 ± 0.22 | 167.66 ± 0.46 | 9.89 ± 0.03 | 60.74 ± 0.41 | |
| 11.49 ± 0.24 | 18.07 ± 0.31 | 16.02 ± 0.24 | 37.82 ± 0.08 | 55.18 ± 0.13 | |
| 6.72 ± 0.37 | 17.89 ± 0.34 | 7.07 ± 0.34 | 9.81 ± 0.03 | 34.64 ± 0.11 | |
| 24.94 ± 0.34 | 12.02 ± 0.09 | 51.53 ± 0.13 | 19.83 ± 0.24 | 5.5 ± 0.08 | |
| <3.901 | 26.31 ± 0.16 | 10.09 ± 0.27 | 5.94 ± 0.04 | 43.19 ± 0.02 | |
| 24.49 ± 0.37 | 100.94 ± 0.17 | 51.33 ± 0.27 | 70.51 ± 0.63 | 52.04 ± 0.45 | |
| 33.46 ± 0.48 | 28.66 ± 0.17 | 83.29 ± 0.19 | 30.32 ± 0.34 | 62.25 ± 0.27 | |
| 53.13 ± 0.19 | 40.28 ± 0.36 | 119.34 ± 0.24 | 36.88 ± 0.72 | 54.77 ± 0.16 | |
| 33.01 ± 0.16 | 731.60 ± 0.28 | 80.98 ± 0.31 | 69.76 ±0.28 | 52.81 ± 0.25 | |
| 5.88 ± 0.34 | 10.06 ± 0.34 | 12.23 ± 0.17 | 24.32 ± 0.11 | 7.76 ± 0.05 | |
| 28.20 ± 0.26 | 62.34 ± 0.19 | 57.06 ± 0.29 | 54.82 ± 0.03 | 51.64 ± 0.26 | |
| 246.14 ± 0.3 | 514.36 ± 0.16 | >1000 | 160.55 ± 0.19 | 76.31 ± 0.25 | |
| <7.81 | <7.81 | <7.81 | 33.92 ± 0.34 | 85.48 ± 0.17 | |
Lipid peroxidation scavenging capacity of coumarin derivatives;
Hydroxy radical scavenging capacity of coumarin derivatives;
Chelating capacity of coumarin derivatives.
Figure 2.(a) and (d) 4-OH bonds of 6b and 4c with (b) and (f) HOMO; (c) and (f) LUMO orbitals of 6b and 4c, respectively.
Bond dissociation enthalpies and the relevant molecular descriptors for the QSAR studies.
| 114.32 | −9.99 | −1.49 | −8.50 | 0.99 | −0.62 | 0 | 0 | 124.41 | −0.529 | |
| 199.74 | −10.01 | −1.56 | −8.45 | 0.99 | −0.66 | 0 | 0 | 203.33 | −1.561 | |
| 227.25 | −9.96 | −1.54 | −8.42 | 1.04 | −0.63 | 0 | 0 | 165.18 | −1.318 | |
| 224.96 | −9.98 | −1.45 | −8.53 | 1.02 | −0.61 | 0 | 0 | 192.32 | −0.035 | |
| 205.84 | −10.04 | −1.65 | −8.39 | 1.03 | −0.67 | 0 | 0 | 171.66 | −1.679 | |
| 211.94 | −10.04 | −1.69 | −8.35 | 1.06 | −0.69 | 0 | 0 | 173.41 | −1.765 | |
| 216.27 | −9.04 | −1.45 | −7.59 | 0.96 | −0.66 | 0 | 0 | 246.34 | −1.709 | |
| 242.37 | −9.00 | −1.95 | −7.05 | 1.55 | −0.61 | −0.59 | 0.25 | 233.72 | 1.216 | |
| 255.69 | −8.99 | −1.62 | −7.37 | 1.53 | −0.46 | −0.62 | 0.27 | 249.55 | 3.129 | |
| 239.26 | −8.90 | −1.13 | −7.77 | 1.63 | −0.65 | −0.31 | 0.29 | 225.94 | 0.702 | |
| 244.56 | −8.92 | −0.94 | −7.78 | 1.36 | −0.70 | −0.66 | 0.47 | 230.13 | 2.904 | |
| 249.78 | −8.89 | −0.95 | −7.94 | 1.59 | −0.67 | −0.68 | 0.27 | 208.37 | 1.921 | |
| 269.29 | −8.91 | −1.07 | −7.84 | 1.69 | −0.63 | −0.69 | 0.26 | 225.74 | 1.856 | |
| 251.48 | −8.97 | −1.76 | −7.21 | 1.61 | −0.68 | −0.62 | 0.24 | 237.20 | 3.380 | |
| 281.35 | −8.87 | −1.23 | −7.64 | 0.99 | −0.65 | −0.64 | 0.25 | 248.00 | 3.129 | |
| 271.52 | −8.79 | −1.16 | −7.63 | 0.99 | −0.65 | −0.65 | 0.26 | 222.34 | 3.603 |
E-energy: E1 BDEs (kcal/mol);
D-descriptor: D1: HOMO (eV); D2: LUMO (eV); D3: H-L gap (eV); D4: 4-OH bond length (Å); D5: Q; D6: Q; D7: Q; D8: CSEV (Å2); D9: log P.
Figure 3.Plot of observed vs. calculated biological values of the training set compounds obtained from (a) Equation (2); (b) Equation (3); (c) Equation (4); (d) Equation (5).
Figure 5.Synthesized coumarin derivatives 1–10c.
Observed vs. calculated values of coumarin derivatives antioxidant activity from QSAR studies.
| 4.01 | 3.89 | 4.06 | 4.26 | 4.57 | 4.78 | 4.71 | 4.80 | 3.32 | 3.42 | |
| 4.32 | 4.71 | 5.34 | 5.43 | 5.12 | 5.18 | 4.76 | 4.72 | 4.34 | 4.37 | |
| 3.70 | 3.69 | 5.06 | 5.11 | 4.92 | 5.14 | 4.49 | 4.62 | 4.24 | 4.36 | |
| 4.07 | 4.88 | 5.00 | 5.09 | 4.72 | 4.82 | 4.06 | 4.13 | 4.20 | 4.44 | |
| 4.29 | 4.28 | 5.61 | 5.65 | 5.41 | 5.41 | 4.84 | 5.02 | 4.54 | 4.44 | |
| 4.45 | 4.76 | 3.87 | 3.75 | 4.12 | 4.18 | 5.00 | 5.13 | 4.22 | 4.52 | |
| 4.00 | 3.89 | 4.95 | 4.96 | 4.94 | 5.08 | 4.42 | 4.47 | 4.26 | 4.36 | |
| 4.47 | 4.91 | 5.16 | 5.25 | 5.17 | 5.48 | 5.00 | 5.23 | 4.46 | 4.52 | |
| 3.88 | 3.92 | 5.03 | 5.13 | 4.60 | 4.92 | 4.70 | 4.86 | 5.26 | 5.31 | |
| 4.76 | 5.01 | 5.45 | 5.69 | 5.41 | 5.61 | 5.23 | 5.55 | 4.36 | 4.26 | |
| 4.27 | 4.14 | 4.12 | 4.06 | 4.66 | 4.63 | 4.15 | 4.26 | 3.28 | 3.34 | |
| 4.14 | 4.08 | 4.63 | 4.80 | 4.47 | 4.73 | 4.52 | 4.72 | 4.21 | 4.21 | |
| 4.33 | 4.36 | 4.22 | 4.42 | 4.27 | 4.38 | 4.43 | 4.44 | 4.26 | 4.26 | |
| 4.32 | 4.445 | 5.32 | 5.68 | 4.48 | 4.56 | 4.16 | 4.22 | 4.28 | 4.45 | |
| 3.86 | 3.15 | 4.12 | 4.12 | 5.23 | 5.53 | 4.61 | 4.71 | 5.11 | 5.34 | |
| 3.66 | 3.49 | 4.06 | 4.26 | 4.55 | 4.72 | 4.12 | 4.32 | 4.29 | 4.26 | |
Correlation matrix of molecular descriptors values and antioxidant activity.
| 1.00 | ||||||||||||||
| 0.48 | 1.00 | |||||||||||||
| 0.96 | 0.91 | 1.00 | ||||||||||||
| 0.48 | 0.51 | 0.37 | 1.00 | |||||||||||
| 0.36 | 0.29 | 0.91 | 0.96 | 1.00 | ||||||||||
| 0.23 | 0.79 | 0.61 | 0.29 | 0.51 | 1.00 | |||||||||
| 0.22 | 0.24 | 0.41 | 0.34 | 0.55 | 0.84 | 1.00 | ||||||||
| 0.11 | 0.13 | 0.24 | 0.09 | 0.38 | 0.31 | 0.41 | 1.00 | |||||||
| 0.26 | 0.42 | 0.35 | 0.14 | 0.18 | 0.31 | 0.29 | 0.19 | 1.00 | ||||||
| 0.97 | 0.74 | 0.00 | 0.00 | 0.87 | 0.64 | 0.79 | 0.00 | 0.12 | 1.00 | |||||
| 0.00 | 0.00 | 0.00 | 0.98 | 0.00 | 0.78 | 0.98 | 0.00 | 0.26 | 0.00 | 1.00 | ||||
| 0.64 | 0.00 | 0.00 | 0.93 | 0.00 | 0.00 | 0.68 | 0.00 | 0.94 | 0.00 | 0.68 | 1.00 | |||
| 0.76 | 0.95 | 0.00 | 0.00 | 0.98 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.34 | 0.17 | 1.00 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.91 | 0.00 | 0.98 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
D- Please see Table 3;
A1: pTAC; A2: pIC; A3: pI; A4: pOH; A5: pCE.
Figure 4.Designed 4-hydroxy-chromene-2H-one structures with predicted biological activity in vitro.